🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 657.57 -0.6% NASDAQ 100: 590.86 -0.7% Dow Jones: 459.32 -0.8%

Steven Cohen’s XLO Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+4 M Shares
Current Position
285,714 Shares
$2.56 M Value

Steven Cohen's XLO Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 285,714 shares of Xilio Therapeutics, Inc. (XLO) worth $2.56 M, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in XLO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Xilio Therapeutics (XLO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Xilio Therapeutics (XLO) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +4 M New Buy 285,714 $8.96

Steven Cohen's Xilio Therapeutics Investment FAQs

Steven Cohen first purchased Xilio Therapeutics, Inc. (XLO) in Q4 2025, acquiring 285,714 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Xilio Therapeutics, Inc. (XLO) for 1 quarters since Q4 2025.

Steven Cohen's largest addition to Xilio Therapeutics, Inc. (XLO) was in Q4 2025, adding 285,714 shares worth $2.56 M.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 285,714 shares of Xilio Therapeutics, Inc. (XLO), valued at approximately $2.56 M.

As of the Q4 2025 filing, Xilio Therapeutics, Inc. (XLO) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Xilio Therapeutics, Inc. (XLO) was 285,714 shares, as reported at the end of Q4 2025.